Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1300
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1180 to $1300.
August 02, 2024 | 7:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Regeneron Pharmaceuticals and raises the price target from $1180 to $1300.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively influence investor sentiment and drive short-term price appreciation for Regeneron Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100